Biomedical Engineering Reference
In-Depth Information
47. The volume of aliquot withdrawn depends on the drug solubility
and the analytical technique being used for quantification.
48. The time points selected should be such that they are able to
provide information about both initial burst release and com-
plete release of the drug from the nanoparticles.
49. To ensure there is no change in the overall volume of the release
medium in the centrifuge tubes over the length of the study,
aliquot withdrawn at any point of time must be replaced with
an equal volume of the same buffer. Moreover, the buffer
should be previously equilibrated to 37
C to maintain physio-
logical conditions. In cumulative drug release analysis, the
volumes removed should be corrected for.
50. If the nanoparticles do not pass through a 32G needle, 30G
needle can be used.
Acknowledgments
This work was supported in part by the NIH grant EY018940. The
authors are thankful to lab members including Puneet Tyagi, Shel-
ley Durazo, Ruchit Trivedi, and Dr. Jiban Jyoti Panda and past lab
member Dr. Sarath Yandrapu for helpful discussions during the
preparation of this chapter.
References
1. Akpek EK, Smith RA (2013) Overview of age-
related ocular conditions. Am J Manag Care 19
(5 Suppl):s67-s75
2. Clark AF, Yorio T (2003) Ophthalmic drug
discovery. Nat Rev Drug Discov
6. D'Souza SS, DeLuca PP (2006) Methods to
assess in vitro drug release from injectable poly-
meric particulate systems. Pharm Res 23
(3):460-474.
doi:
10.1007/s11095-005-
9397-8
7. Singh SR, Grossniklaus HE, Kang SJ, Edelhau-
ser HF, Ambati BK, Kompella UB (2009)
Intravenous transferrin, RGD peptide and
dual-targeted nanoparticles enhance anti-
VEGF intraceptor gene delivery to laser-
induced CNV. Gene Ther 16(5):645-659.
doi:
10.1038/gt.2008.185
8. Mitra M, Misra R, Harilal A, Sahoo SK,
Krishnakumar S (2011) Enhanced in vitro anti-
proliferative effects of EpCAM antibody-
functionalized paclitaxel-loaded PLGAnanopar-
ticles
2
(6):448-459. doi:
10.1038/nrd1106
3. Shah SS, Denham LV, Elison JR, Bhattacharjee
PS, Clement C, Huq T, Hill JM (2010) Drug
delivery to the posterior segment of the eye for
pharmacologic therapy. Exp Rev Ophthalmol 5
(1):75-93. doi:
10.1586/eop.09.70
4. Amrite AC, Ayalasomayajula SP, Cheruvu NP,
Kompella UB (2006) Single periocular injec-
tion of celecoxib-PLGA microparticles inhibits
diabetes-induced elevations in retinal PGE2,
VEGF, and vascular leakage. Invest Ophthal-
mol Vis Sci 47(3):1149-1160. doi:
10.1167/
iovs.05-0531
5. Kompella UB, Amrite AC, Pacha Ravi R, Dur-
azo SA (2013) Nanomedicines for back of the
eye drug delivery, gene delivery, and imaging.
Prog Retin Eye Res. doi:
10.1016/j.preteyeres.
2013.04.001
in
retinoblastoma
cells. Mol Vis
17:2724-2737
9. Astete CE, Sabliov CM (2006) Synthesis and
characterization of PLGA nanoparticles. J Bio-
mater Sci Polym Ed 17(3):247-289
10. Peyman GA, Yang D, Khoobehi B, Rahimy
MH, Chin SY (1996) In vitro evaluation of
